YMAB logo

Y-mAbs Therapeutics, Inc. (YMAB)

Profile

Full Name

Y-mAbs Therapeutics, Inc.

Ticker

NASDAQ: YMAB

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

September 21, 2018

Indexes

Not included

Website

https://www.ymabs.com

Employees

104

Key Details

Price

$8.61

Market Cap

$391.22M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$87.69M(3.38% YoY)

Annual EPS

-$0.67(-36.73% YoY)

PE Ratio

-

Next earnings date

Nov 6, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $8.61
    YMAB price is $8.61

    30-Day Relative Volume

    0.00
    YMAB 30-day relative volume is 0.00

    Price Performance

    Price Most Recent Change

    -
    YMAB price change on Sep 16, 2025 is unknown

    Price YTD Change

    +9.96%
    YMAB price is up +9.96% since January 1st

    Price 1-Year Change

    -38.76%
    YMAB price is down -38.76% year-on-year

    Price 3-Year Change

    -37.56%
    YMAB price is down -37.56% over the past 3 years

    Price Range

    Price All-Time High

    $55.22
    YMAB price is currently -84.41% below its historical high of $55.22

    Price 3-Year Low

    $2.70
    YMAB price is currently +218.89% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market Cap

    $391.22M
    YMAB market cap is $391.22 million

    Market Cap 3-Year Change

    -35.03%
    YMAB market cap is down -35.03% over the past 3 years

    Market Cap All-Time High

    $2.20B
    YMAB market cap is currently -82.20% below its historical high of $2.20 billion

    Market Cap Sector Percentile

    -
    YMAB market cap is unknown

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +1.5%
    YMAB shares outstanding is up +1.5% year-on-year

    Shares Outstanding 3-Year Change

    +4.05%
    YMAB shares outstanding is up +4.05% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    0.91
    YMAB beta is 0.91

    200-day SMA

    $6.11
    YMAB price is currently +40.97% above its 200-day simple moving average

    50-day SMA

    $6.93
    YMAB price is currently +24.25% above its 50-day simple moving average

    14-Day RSI

    81.19
    YMAB 14-day relative strength index is 81.19

    Volume

    0.00
    YMAB 30-day relative volume is 0.00

    ATR

    $0.08
    YMAB average true range is $0.08

    10-day Historical Volatility

    2.01%
    YMAB 10-day historical volatility is 2.01%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $87.69M
    YMAB annual revenue is $87.69 million

    Revenue Analysts Estimate

    $82.95M
    YMAB annual revenue is currently +5.71% higher than the consensus analysts' forecast

    Revenue 1-Year Change

    +3.38%
    YMAB annual revenue is up +3.38% year-on-year

    Revenue Sector Percentile

    -
    YMAB annual revenue is unknown

    EPS

    EPS

    -$0.67
    YMAB annual earnings per share is -$0.67

    EPS Analysts Estimate

    -$0.86
    YMAB annual earnings per share is currently +22.09% higher than the consensus analysts' forecast

    EPS 1-Year Change

    -36.73%
    YMAB annual earnings per share is down -36.73% year-on-year

    EPS Sector Percentile

    -
    YMAB annual earnings per share is unknown

    Profit

    Gross Profit

    $72.43M
    YMAB annual gross profit is $72.43 million

    Gross Margin

    82.61%
    YMAB annual gross profit margin is 82.61%

    Operating Profit

    -$31.20M
    YMAB annual operating income is -$31.20 million

    Operating Margin

    -33.85%
    YMAB annual operating profit margin is -33.85%

    Net Income

    -$29.67M
    YMAB annual net profit is -$29.67 million

    Net Margin

    -33.83%
    YMAB annual net profit margin is -33.83%

    Expenses

    Total Expenses

    $118.89M
    YMAB annual total expenses is $118.89 million

    Operating Expenses

    $103.64M
    YMAB annual total operating expenses is $103.64 million

    Cost Of Goods Sold

    $15.25M
    YMAB annual cost of goods sold is $15.25 million

    Selling, General & Administrative Expenses

    $54.65M
    YMAB annual SG&A is $54.65 million

    Depreciation & Amortization

    $535.00K
    YMAB annual D&A is $535.00 thousand

    Interest Expense

    $0.00
    YMAB annual interest expense is $0.00

    Income Tax

    -$146.00K
    YMAB annual income tax is -$146.00 thousand

    EBIT & EBITDA

    EBIT

    -$31.20M
    YMAB annual earnings before interest & taxes is -$31.20 million

    EBITDA

    -$30.67M
    YMAB annual EBITDA is -$30.67 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total Assets

    $119.90M
    YMAB annual total assets is $119.90 million

    Non Current Assets

    $21.39M
    YMAB annual long term assets is $21.39 million

    Current Assets

    $98.51M
    YMAB annual total current assets is $98.51 million

    Cash and Cash Equivalents

    $67.23M
    YMAB annual cash & cash equivalents is $67.23 million

    Accounts Receivable

    $19.69M
    YMAB annual accounts receivable is $19.69 million

    Inventory

    $7.21M
    YMAB annual inventory is $7.21 million

    Liabilities

    Total Liabilities

    $27.90M
    YMAB annual total liabilities is $27.90 million

    Long Term Liabilities

    $4.20M
    YMAB annual total long term liabilities is $4.20 million

    Current Liabilities

    $23.70M
    YMAB annual current liabilities is $23.70 million

    Accounts Payable

    $6.66M
    YMAB annual accounts payable is $6.66 million

    Debt

    Total Debt

    $820.00K
    YMAB annual total debt is $820.00 thousand

    Total Debt 1-Year Change

    -42.21%
    YMAB annual total debt is down -42.21% year-on-year

    Long Term Debt

    $190.00K
    YMAB annual long term debt is $190.00 thousand

    Short Term Debt

    $630.00K
    YMAB annual short term debt is $630.00 thousand

    Equity & Capital

    Shareholders Equity

    $92.00M
    YMAB annual stockholders equity is $92.00 million

    Book Value

    $92.00M
    YMAB annual book value is $92.00 million

    Retained Earnings

    -$487.14M
    YMAB annual retained earnings is -$487.14 million

    Working Capital

    $74.81M
    YMAB annual working capital is $74.81 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash From Operations

    -$15.71M
    YMAB annual cash from operations is -$15.71 million

    Cash From Operations 1-Year Change

    +42.3%
    YMAB annual cash from operations is up +42.3% year-on-year

    Cash From Investing

    $0.00
    YMAB annual cash from investing is $0.00

    Cash From Investing 1-Year Change

    0%
    YMAB annual cash from investing has remained unchanged year-on-year

    Cash From Financing

    $4.31M
    YMAB annual cash from financing is $4.31 million

    Cash From Financing 1-Year Change

    +4211%
    YMAB annual cash from financing is up +4211% year-on-year

    CAPEX

    CAPEX

    $0.00
    YMAB annual capital expenditures is $0.00

    CAPEX 1-Year Change

    0%
    YMAB annual capital expenditures has remained unchanged year-on-year

    Free Cash Flow

    Free Cash Flow

    -$15.71M
    YMAB annual free cash flow is -$15.71 million

    Free Cash Flow 1-Year Change

    +42.3%
    YMAB annual free cash flow is up +42.3% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross Margin

    82.61%
    YMAB annual gross profit margin is 82.61%

    Operating Margin

    -33.85%
    YMAB annual operating profit margin is -33.85%

    Net Margin

    -33.83%
    YMAB annual net profit margin is -33.83%

    ROA & ROE

    ROA

    -23.95%
    YMAB annual return on assets is -23.95%

    ROE

    -30.74%
    YMAB annual return on equity is -30.74%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE Ratio

    -
    YMAB price to earnings ratio value is unknown

    PE Ratio Sector Percentile

    -
    YMAB price to earnings ratio is unknown

    PB Ratio

    PB Ratio

    4.47
    YMAB price to book ratio is 4.47

    PB Ratio Sector Percentile

    -
    YMAB price to book ratio is unknown

    PS Ratio

    PS Ratio

    4.58
    YMAB price to sales ratio is 4.58

    PS Ratio Sector Percentile

    -
    YMAB price to sales ratio is unknown

    Enterprise value

    Enterprise Value

    $332.06M
    YMAB enterprise value is $332.06 million

    Enterprise Value Sector Percentile

    -
    YMAB enterprise value is unknown

    EV/EBITDA

    EV/EBITDA

    -12.62
    YMAB EV/EBITDA is -12.62

    EV/EBITDA Sector Percentile

    -
    YMAB EV/EBITDA is unknown

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current Ratio

    4.16
    YMAB annual current ratio is 4.16

    Quick Ratio

    3.85
    YMAB annual quick ratio is 3.85

    Leverage

    Debt To Equity

    0.01
    YMAB annual debt to equity ratio is 0.01

    Interest Coverage Ratio

    -
    YMAB annual interest coverage ratio value is unknown

    Risk & Stability

    F-Score

    3
    YMAB piotroski f-score is 3

    Altman Z-Score

    3.35
    YMAB altman z-score is 3.35

    Analyst ratings

    Recent major analysts updates

    Aug 6, 25 HC Wainwright & Co.
    Neutral
    Aug 6, 25 Canaccord Genuity
    Hold
    Aug 5, 25 Jones Trading
    Hold
    May 29, 25 Oppenheimer
    Outperform
    May 19, 25 HC Wainwright & Co.
    Buy
    May 14, 25 Truist Securities
    Buy
    May 14, 25 Oppenheimer
    Outperform
    Mar 21, 25 HC Wainwright & Co.
    Buy
    Mar 5, 25 Truist Securities
    Buy
    Mar 5, 25 Morgan Stanley
    Underweight

    Institutional Ownership

    Screeners with YMAB included

    No data
    • What is the ticker symbol for Y-mAbs Therapeutics, Inc.?
    • Does Y-mAbs Therapeutics, Inc. pay dividends?
    • What sector is Y-mAbs Therapeutics, Inc. in?
    • What industry is Y-mAbs Therapeutics, Inc. in?
    • What country is Y-mAbs Therapeutics, Inc. based in?
    • When did Y-mAbs Therapeutics, Inc. go public?
    • Is Y-mAbs Therapeutics, Inc. in the S&P 500?
    • Is Y-mAbs Therapeutics, Inc. in the NASDAQ 100?
    • Is Y-mAbs Therapeutics, Inc. in the Dow Jones?
    • When was Y-mAbs Therapeutics, Inc.'s last earnings report?
    • When does Y-mAbs Therapeutics, Inc. report earnings?

    What is the ticker symbol for Y-mAbs Therapeutics, Inc.?

    The ticker symbol for Y-mAbs Therapeutics, Inc. is NASDAQ:YMAB

    Does Y-mAbs Therapeutics, Inc. pay dividends?

    No, Y-mAbs Therapeutics, Inc. does not pay dividends

    What sector is Y-mAbs Therapeutics, Inc. in?

    Y-mAbs Therapeutics, Inc. is in the Healthcare sector

    What industry is Y-mAbs Therapeutics, Inc. in?

    Y-mAbs Therapeutics, Inc. is in the Biotechnology industry

    What country is Y-mAbs Therapeutics, Inc. based in?

    Y-mAbs Therapeutics, Inc. is headquartered in United States

    When did Y-mAbs Therapeutics, Inc. go public?

    Y-mAbs Therapeutics, Inc.'s initial public offering (IPO) was on September 21, 2018

    Is Y-mAbs Therapeutics, Inc. in the S&P 500?

    No, Y-mAbs Therapeutics, Inc. is not included in the S&P 500 index

    Is Y-mAbs Therapeutics, Inc. in the NASDAQ 100?

    No, Y-mAbs Therapeutics, Inc. is not included in the NASDAQ 100 index

    Is Y-mAbs Therapeutics, Inc. in the Dow Jones?

    No, Y-mAbs Therapeutics, Inc. is not included in the Dow Jones index

    When was Y-mAbs Therapeutics, Inc.'s last earnings report?

    Y-mAbs Therapeutics, Inc.'s most recent earnings report was on August 8, 2025

    When does Y-mAbs Therapeutics, Inc. report earnings?

    The next expected earnings date for Y-mAbs Therapeutics, Inc. is November 6, 2025
    On this page